BayOne bridges "living behavior" and drug discovery — an AI-powered phenomics and intelligent pharmacodynamics platform integrating artificial intelligence across the full drug discovery pipeline.
A New Direction for Drug Discovery
As traditional molecular targets hit bottlenecks, drug discovery needs a wider horizon. Large-scale automated phenotyping turns fragmented biology into precise efficacy readouts — giving your pipeline a systems-level view.
BayOne addresses the need for richer screening readouts in neurological disease — combining high-throughput imaging, AI behavior capture, and deep omics to build detailed behavioral fingerprint maps across animal models.
Our behavioral atlas reframes drug identification — high-throughput phenotypic assessment reveals how compounds affect the living system as a whole, elevating screening and safety evaluation to a new level.
BayOne announces a strategic partnership with Safegene and Pulin Bio to launch pharmacodynamic assessment based on NHP large-animal behavioral phenotypes.
Multi-pharma collaborations leverage full-spectrum behavioral phenotyping to develop CNS lead compounds toward safer, more effective therapies.
Prof. Li Cheng (Shanghai Fourth Hospital) and Prof. Hu Ji (ShanghaiTech) used the BAYONE fine behavior platform to show dexmedetomidine significantly prevents delirium — strong preclinical evidence for clinical translation.
Contact us about AI phenomics platforms, efficacy assessment workflows, and co-development partnerships.